<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00487318</url>
  </required_header>
  <id_info>
    <org_study_id>13358</org_study_id>
    <nct_id>NCT00487318</nct_id>
  </id_info>
  <brief_title>Fluvastatin, Rosuvastatin Added to Pegylated Interferon and Ribavirin</brief_title>
  <official_title>A Randomized Controlled Trial of Adding Fluvastatin to Standard Medical Treatment (SMT) and a Pilot Trial of Rosuvastatin and Other Statins With SMT, for Patients Infected With Chronic Hepatitis C Who Are Naive to Therapy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bader, Ted, M.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Bader, Ted, M.D.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypothesis: addition of fluvastatin will increase the cure rate of standard anti-HCV therapy.
      Summary: This trial is limited to veterans in Oklahoma who qualify for care with the Veterans
      Administration. It is a randomized control format including genotypes 1 and 3. There will
      also be pilot arms for HCV carriers who present for screening already on a statin, who will
      be allowed to stay on their current statin or switched to another statin. In all ways,
      standard therapy as noted on pegylated interferon and ribavirin will be given per FDA package
      insert.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sustained Viral response</measure>
    <time_frame>72 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Viral load at 4, 12 and 24 weeks</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Chronic Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Arm 1 Plus statin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The addition of fluvastatin or rosuvastatin or other statins to the standard of care of peginterferon and ribavirin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Administration of the standard of care for hepatitis C of peginterferon and ribavirin.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>standard of care</intervention_name>
    <description>peginterferon/RBV</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluvastatin</intervention_name>
    <description>Add fluvastatin at 20-40 mg/day to standard of care</description>
    <arm_group_label>Arm 1 Plus statin</arm_group_label>
    <other_name>Lescol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Not previously treated.

          -  Off alcohol and marijuana for 6 months

          -  HCV RNA positive

        Exclusion Criteria:

          -  HIV positive

          -  Advanced liver disease

          -  Advanced cardiopulmonary disease

          -  Chronic renal failure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ted F Bader, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>OUHSC and VAMC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Veterans Administration Medical Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 15, 2007</study_first_submitted>
  <study_first_submitted_qc>June 15, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 18, 2007</study_first_posted>
  <last_update_submitted>August 20, 2012</last_update_submitted>
  <last_update_submitted_qc>August 20, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 21, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Bader, Ted, M.D.</investigator_affiliation>
    <investigator_full_name>Ted Bader, MD</investigator_full_name>
    <investigator_title>Director of Liver Diseases, VA Medical Center</investigator_title>
  </responsible_party>
  <keyword>fluvastatin</keyword>
  <keyword>hepatitis C</keyword>
  <keyword>chronic hepatitis C</keyword>
  <keyword>not previously treated with pegylated interferon and ribavirin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Rosuvastatin Calcium</mesh_term>
    <mesh_term>Fluvastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

